Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU

Authors: Shona Brothwell, Mary Dutton, Charles Ferro, Stephanie Stringer, Paul Cockwell

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Accurate blood pressure monitoring is critical for the management of chronic kidney disease, but changes in management in secondary care clinics may be based on a single blood pressure reading, with a subsequent lack of accuracy. The aim of this study was to evaluate a fully automated sphygmomanometer for optimising the accuracy of blood pressure measurements in the setting of secondary care renal clinics.

Methods

Patients had routine blood pressure measurements with a calibrated DINAMAP PRO400 monitor in a clinical assessment room. Patients then underwent repeat assessment with a DINAMAP PRO400 monitor and BpTRU device and subsequent 24 hour ambulatory blood pressure monitoring (ABPM).

Results

The BpTRU systolic (± SD) reading (117.3 ± 14.1 mmHg) was significantly lower than the routine clinic mean systolic blood pressure (143.8 ± 15.5 mmHg; P < 0.001) and the repeat blood pressure taken with a DINAMAP PRO400 monitor in a quiet room (129.9 ± 19.9 mmHg; P < 0.001). The routine clinic mean diastolic (82.4 ± 11.2 mmHg) was significantly higher than the BpTRU reading (78.4 ± 10.0 mmHg; P < 0.001). Clinic BpTRU measurements were not significantly different to the daytime mean or overall mean of 24 hour ABPM.

Conclusions

In patients with CKD, routine clinic blood pressure measurements were significantly higher than measurements using a BpTRU machine in a quiet room, but there was no significant difference in this setting between BpTRU readings and 24 hour ABPM. Adjusting clinic protocols to utilise the most accurate blood pressure technique available is a simple manoeuvre that could deliver major improvements in clinical practice.
Appendix
Available only for authorised users
Literature
1.
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003, 41: 1-12.CrossRefPubMed
2.
Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, the Chronic Kidney Disease Prognosis Consortium: Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011, 80: 93-104. 10.1038/ki.2010.531.CrossRefPubMedPubMedCentral
3.
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt K-U: The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011, 80: 17-28. 10.1038/ki.2010.483.CrossRefPubMed
4.
Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure. JAMA. 2011, 305 (15): 1553-1559. 10.1001/jama.2011.451.CrossRefPubMed
5.
Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med. 2001, 161: 1207-1216. 10.1001/archinte.161.9.1207.CrossRefPubMed
6.
Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, Bakris GL: Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008, 121: 332-340. 10.1016/j.amjmed.2007.11.025.CrossRefPubMed
7.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med. 1994, 330: 877-884. 10.1056/NEJM199403313301301.CrossRefPubMed
8.
Jacobsen P, Rossing K, Tarnow L, Rossing P, Mallet C, Poirier O, Cambien F, Parving HH: Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 1999, 56 (Suppl 71): 101-105.CrossRef
9.
Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G: Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol. 2006, 17 (Suppl 2): 98-103.CrossRef
10.
National Institute for Health and Clinical Excellence (NICE) clinical guideline 73: Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care. 2008
11.
Reeves RA: Does this patient have hypertension? How to measure blood pressure. JAMA. 1995, 273: 1211-1218. 10.1001/jama.1995.03520390071036.CrossRefPubMed
12.
Birkett NJ: The effect of alternative criteria for hypertension on estimates of prevalence and control. J Hypertens. 1997, 15: 237-244. 10.1097/00004872-199715030-00004.CrossRefPubMed
13.
McAlister FA, Straus SE: Evidence based treatment of hypertension. Measurement of blood pressure: an evidence based review. BMJ. 2001, 322 (7291): 908-911. 10.1136/bmj.322.7291.908.CrossRefPubMedPubMedCentral
14.
Pickering TG: Blood pressure measurement and detection of hypertension. Lancet. 1994, 344 (8914): 31-35. 10.1016/S0140-6736(94)91053-7.CrossRefPubMed
15.
Agarwal R, Anderson MJ: Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006, 69: 406-411. 10.1038/sj.ki.5000081.CrossRefPubMed
16.
Staessen JA, Byttebier G, Buntinx F, Celis H, O’Brien ET, Fagard R: Antihypertensive treatment based on conventional or ambulatory blood pressure measurement: a randomized controlled trial. JAMA. 1997, 278: 1065-1072. 10.1001/jama.1997.03550130039034.CrossRefPubMed
17.
Pickering TG, Davidson K, Gerin W, Schwartz JE: Masked hypertension. Hypertension. 2002, 40: 795-796. 10.1161/01.HYP.0000038733.08436.98.CrossRefPubMed
18.
Lorgelly P, Siatis I, Brooks A, Slinn B, Millar-Craig MW, Donnelly R, Manning G: Is ambulatory blood pressure monitoring cost-effective in the routine surveillance of treated hypertensive patients in primary care?. Br J Gen Pract. 2003, 53 (495): 794-796.PubMedPubMedCentral
19.
Andersen MJ, Khawandi W, Agarwal R: Home blood pressure monitoring in CKD. Am J Kidney Dis. 2005, 45: 994-1001. 10.1053/j.ajkd.2005.02.015.CrossRefPubMed
20.
Bangash F, Agarwal R: Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2009, 4 (3): 656-664. 10.2215/CJN.05391008.CrossRefPubMedPubMedCentral
21.
22.
Linfors EW, Feussner JR, Blessing CL, Starmer CF, Neelon FA, McKee PA: Spurious hypertension in the obese patient. Effect of sphygmomanometer cuff size on prevalence of hypertension. Arch Intern Med. 1984, 144: 1482-1485. 10.1001/archinte.1984.00350190188032.CrossRefPubMed
23.
Cushman WC, Cooper KM, Horne RA, Meydrech EF: Effect of back support and stethoscope head position on seated blood pressure determinations. Am J Hypertens. 1990, 3: 240-241.PubMed
24.
Veerman DP, Van Montfrans GA, Wieling W: Effects of cuff inflation on self-recorded blood pressure. Lancet. 1990, 335: 451-453. 10.1016/0140-6736(90)90676-V.CrossRefPubMed
25.
Graves JW, Nash C, Burger K, Bailey K, Sheps SG: Clinical decision-making in hypertension using an automated (BpTRU) measurement device. J Hum Hypertens. 2003, 17 (12): 823-827. 10.1038/sj.jhh.1001626.CrossRefPubMed
26.
Wright JM, Mattu GS, Perry TL, Gelfer ME, Strange KD, Zorn A, Chen Y: Validation of new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor. Blood Press Monit. 2001, 6: 161-165. 10.1097/00126097-200106000-00008.CrossRefPubMed
27.
White WG, Anwar YA: Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adults. Blood Press Monit. 2001, 6: 107-110. 10.1097/00126097-200104000-00007.CrossRefPubMed
28.
Stergiou GS, Tzamouranis D, Protogerou A, Nasothimiou E, Kapralos C: Validation of Microlife Watch BP Office Professional device for office blood pressure measurement according to the international protocol. Blood Press Monit. 2008, 13: 299-303. 10.1097/MBP.0b013e3283057af6.CrossRefPubMed
29.
Beckett L, Godwin M: The BpTRU automatic blood pressure monitor compared to 24-h ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2005, 5: 18-10.1186/1471-2261-5-18.CrossRefPubMedPubMedCentral
30.
Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FDR, Hodgkinson J, Mant J, Martin U, Williams B, Wonderling D, McManus RJ: Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011, 378: 1219-1230. 10.1016/S0140-6736(11)61184-7.CrossRefPubMed
31.
Agarwal R, Andersen MJ: Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension. 2005, 46: 514-520. 10.1161/01.HYP.0000178102.85718.66.CrossRefPubMed
32.
Agarwal R, Peixoto AJ, Santos SFF, Zoccali C: Out-of-office blood pressure monitoring in chronic kidney disease. Blood Press Monit. 2009, 14: 2-11. 10.1097/MBP.0b013e3283262f58.CrossRefPubMed
33.
Davidson MB, Hix JK, Vidt DG, Brotman DJ: Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med. 2006, 166: 846-852. 10.1001/archinte.166.8.846.CrossRefPubMed
34.
Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA: African American study of kidney disease and hypertension collaborative research group: disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009, 53: 20-27. 10.1161/HYPERTENSIONAHA.108.115154.CrossRefPubMed
35.
Mojón A, Ayala DE, Piñeiro L, Otero A, Crespo JJ, Moyá A, Bóveda J, Pérez de Lis J, Fernández JR, Hermida RC: Comparison of Ambulatory Blood Pressure Parameters of Hypertensive Patients With and Without Chronic Kidney Disease. Chronobiol Int. 2013, 30 (1–2): 145-158.CrossRefPubMed
36.
Hermida RC, Ayala DE, Mojón A, Fernández JR: Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011, 22: 2313-2321. 10.1681/ASN.2011040361.CrossRefPubMedPubMedCentral
37.
Liu M, Takahashi H, Morita Y: Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant. 2003, 18: 563-569. 10.1093/ndt/18.3.563.CrossRefPubMed
38.
Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V, Nappi F, Cianciaruso B, Zamboni P, Conte G, Gabbai FB, De Nicola L: Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med. 2011, 171: 1090-1098. 10.1001/archinternmed.2011.230.CrossRefPubMed
39.
Tripepi G, Fagugli RM, Dattolo P, Parlongo G, Mallamaci F, Buoncristiani U, Zoccali C: Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney Int. 2005, 68: 1294-1302. 10.1111/j.1523-1755.2005.00527.x.CrossRefPubMed
40.
Crespo JJ, Piñeiro L, Otero A, Castiñeira C, Ríos MT, Regueiro A, Mojón A, Lorenzo S, Ayala DE, Hermida RC: Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease. Chronobiol Int. 2013, 30 (1–2): 159-175.CrossRefPubMed
41.
Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen CH, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O’Brien E, Staessen JA: Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007, 370: 1219-1229. 10.1016/S0140-6736(07)61538-4.CrossRefPubMed
42.
Brotman DJ, Davidson MB, Boumitri M, Vidt DG: Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008, 21: 92-97. 10.1038/ajh.2007.7.CrossRefPubMed
43.
Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O’Brien E: Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005, 46: 156-161. 10.1161/01.HYP.0000170138.56903.7a.CrossRefPubMed
44.
Eguchi K, Pickering TG, Hoshide S, Ishikawa J, Ishikawa S, Schwartz J, Shimada K, Kario K: Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. Am J Hypertens. 2008, 21: 443-450. 10.1038/ajh.2008.4.CrossRefPubMed
45.
Hermida RC, Ayala DE, Mojón A, Fernández JR: Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens. 2012, 25: 325-334. 10.1038/ajh.2011.231.CrossRefPubMed
46.
Hermida RC, Ayala DE, Fernández JR, Mojón A: Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Chronobiol Int. 2013, 30: 68-86. 10.3109/07420528.2012.702581.CrossRefPubMed
47.
Hermida RC, Ayala DE, Mojón A, Fernández JR: Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level—the “normotensive nondipper” paradox. Chronobiol Int. 2013, 30: 87-98. 10.3109/07420528.2012.701127.CrossRefPubMed
48.
Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K: Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal events in NIDDM subjects. Diabetes. 1998, 47: 1501-1506. 10.2337/diabetes.47.9.1501.CrossRefPubMed
49.
Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y: Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002, 20: 2183-2189. 10.1097/00004872-200211000-00017.CrossRefPubMed
50.
Sturrock ND, George E, Pound N, Stevenson J, Peck GM, Sowter H: Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med. 2000, 17: 360-364. 10.1046/j.1464-5491.2000.00284.x.CrossRefPubMed
51.
Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G: Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994, 24: 793-801. 10.1161/01.HYP.24.6.793.CrossRefPubMed
52.
Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D: Comparison of acceptability and preferences for different methods of measuring blood pressure in primary care. BMJ. 2002, 325: 258-259. 10.1136/bmj.325.7358.258.CrossRefPubMedPubMedCentral
53.
Myers MG, Valdivieso M, Chessman M, Kiss A: Can sphygmomanometers designed for self-measurement of blood pressure in the home be used in office practice?. Blood Press Monit. 2010, 15 (6): 300-304. 10.1097/MBP.0b013e328340d128.CrossRefPubMed
54.
Godwin M, Birtwhistle R, Delva D, Lam M, Casson I, MacDonald S, Seguin R: Manual and automated office measurements in relation to awake ambulatory blood pressure monitoring. Fam Pract. 2011, 28: 110-117. 10.1093/fampra/cmq067.CrossRefPubMed
55.
Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, Kaczorowski J: Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ. 2011, 342: d286-10.1136/bmj.d286.CrossRefPubMedPubMedCentral
56.
O’Shaughnessy MM, Newman CA, Kinsella SM, Reddan DN, Lappin DW: In-office assessment of blood pressure in chronic kidney disease: usual measurement versus automated BpTRU measurement. Blood Press Monit. 2011, 16 (3): 124-128. 10.1097/MBP.0b013e328346e0db.CrossRefPubMed
57.
Ni K, Wu C, Prineas R, Shea S, Liu K, Kronmal R, Bild D: Comparison of Dinamap Pro-100 and mercury sphygmomanometer blood pressure measurements in a population based study. Am J Hypertension. 2006, 19: 353-360. 10.1016/j.amjhyper.2005.10.020.CrossRef
58.
Myers MG, Valdivieso M, Kiss A: Optimum frequency of office blood pressure measurement using an automated sphygmomanometer. Blood Press Monit. 2008, 13 (6): 333-338. 10.1097/MBP.0b013e3283104247.CrossRefPubMed
59.
O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, the European Society of Hypertension Working Group on Blood Pressure Monitoring: European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertension. 2003, 21: 821-848. 10.1097/00004872-200305000-00001.CrossRef
60.
Myers MG, McInnis NH, Fodor GJ, Leenen FH: Comparison between an automated and manual sphygmomanometer in a population survey. Am J Hypertens. 2008, 21 (3): 280-283. 10.1038/ajh.2007.54.CrossRefPubMed
61.
Myers MG: Automated blood pressure measurement in routine clinical practice. Blood Press Monit. 2006, 11: 59-62. 10.1097/01.mbp.0000200481.64787.c0.CrossRefPubMed
62.
Hermida RC, Smolensky MH: Chronotherapy of hypertension. Curr Opin Nephrol Hypertens. 2004, 13: 501-505. 10.1097/00041552-200409000-00004.CrossRefPubMed
63.
Hermida RC, Ayala DE, Calvo C: Administration time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure. Curr Opin Nephrol Hypertens. 2005, 14: 453-459. 10.1097/01.mnh.0000174144.07174.74.CrossRefPubMed
64.
Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH: Chronotherapy of hypertension: administration-time dependent effects of treatment on the circadian pattern of blood pressure. Adv Drug Deliv Rev. 2007, 59: 923-939. 10.1016/j.addr.2006.09.021.CrossRefPubMed
65.
Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR: Chronotherapy with valsartan/amlodipine combination in essential hypertension: improved blood pressure control with bedtime dosing. Chronobiol Int. 2010, 27: 1287-1303. 10.3109/07420528.2010.489167.CrossRefPubMed
66.
Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH: Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens. 2011, 24: 383-391. 10.1038/ajh.2010.217.CrossRefPubMed
67.
Hermida RC, Ayala DE, Mojón A, Fontao MJ, Fernández JR: Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int. 2011, 28: 601-610. 10.3109/07420528.2011.589935.CrossRefPubMed
68.
Hermida RC, Ayala DE, Fernández JR, Mojón A, Smolensky MH, Fabbian F, Portaluppi F: Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int. 2013, 30: 280-314. 10.3109/07420528.2012.709448.CrossRefPubMed
69.
Hermida RC, Ayala DE, Mojón A, Fernández JR: Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Chronobiol Int. 2013, 30: 315-327. 10.3109/07420528.2012.701534.CrossRefPubMed
70.
Portaluppi F, Smolensky MH: Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study. Chronobiol Int. 2010, 27: 1652-1667. 10.3109/07420528.2010.510788.CrossRefPubMed
71.
Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F: Administration-time-dependent effect of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010, 15: 173-180. 10.1097/MBP.0b013e32833c7308.CrossRefPubMed
72.
Ayala DE, Hermida RC, Mojón A, Fernández JR: Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int. 2013, 30: 340-352. 10.3109/07420528.2012.701455.CrossRefPubMed
73.
Hermida RC, Ayala DE, Mojón A, Fernández JR: Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010, 27: 1629-1651. 10.3109/07420528.2010.510230.CrossRefPubMed
74.
Hermida RC, Ayala DE, Mojón A, Fernández JR: Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011, 58: 1165-1173. 10.1016/j.jacc.2011.04.043.CrossRefPubMed
75.
Hermida RC, Ayala DE, Mojón A, Fernández JR: Influence of time of day of blood pressure lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011, 34: 1270-1276. 10.2337/dc11-0297.CrossRefPubMedPubMedCentral
76.
Hermida RC, Smolensky MH, Ayala DE, Portaluppi F, Crespo JJ, Fabbian F, Haus E, Manfredini R, Mojón A, Moyá A, Piñeiro L, Ríos MT, Otero A, Balan H, Fernández JR: 2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiology Int. 2013, 30 (3): 355-410. 10.3109/07420528.2013.750490.CrossRef
77.
The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2013 ESH/ ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013, 10.1093/eurheartj/eht151
78.
National Institute for Health and Clinical Excellence (NICE) clinical guideline 127: Clinical management of primary hypertension in adults. 2011
Metadata
Title
Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU
Authors
Shona Brothwell
Mary Dutton
Charles Ferro
Stephanie Stringer
Paul Cockwell
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-218

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue

Research article

Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease

Research article

Hemodialysis and hemodiafiltration differently modulate left ventricular diastolic function

Research article

Modelling competing risks in nephrology research: an example in peritoneal dialysis

Research article

Competing-risk analysis of death and dialysis initiation among elderly (≥80 years) newly referred to nephrologists: a French prospective study

Research article

Angiopoietin-1 treated early endothelial outgrowth cells (eEOCs) are activated in vitro and reduce renal damage in murine acute ischemic kidney injury (iAKI)

Case report

Erythropoietin-producing tubercle granuloma in a hemodialysis patient
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits